

Berichtstitel: Studien Administration-Liste

Datum und Uhrzeit der Ausführung: 03.06.2024 09:47:55 Central European Summer Time

Ausgeführt von: May Jane Erne (I0326428)

Tabellenname: u_contract_management

Abfragebedingung: Eröffnet von ist May Jane Erne (I0326428) .or. DLF Administrator ist May Jane Erne (I0326428) .or. Studienteam ENTHÄLT (May Jane Erne (I0326428)) .or. Studienleiter ist May Jane Erne (I0326428) AND Status = Durchführung

Sortierreihenfolge: SN-ID in aufsteigender Reihenfolge

32 Studien Administrationen

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	1043	STD0001995	061/05	Dagmar Simon (I0068240)		Skin immunity and barrier function in chronic inflammatory skin diseases.	31.05.2005	30.12.2025
Durchführung	1975	STD0002908	201/10	Dagmar Simon (I0068240)		Epikutane Testung von Kosmetikprodukten zur Abklärung der Hautverträglichkeit.	30.11.2010	30.12.2027
Durchführung	2004	STD0002937	192/10	Laurence Feldmeyer (I0310392)		Oral lichen planus versus oral lichenoid lesions: A clinical study focussing on differential diagnosis, characterization of the Disease and follow up.	28.02.2011	31.12.2025

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	2113	STD0003046	130/11 PB_2016-01782	Luca Borradori (I0082973)	SDNTT	Swiss Dermatology Network for Targeted Therapies (SDNTT): Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational Cooperation with CVderm in Hamburg.	30.09.2011	30.10.2025
Durchführung	2383	STD0003316	088/13	Christoph Schlapbach (I0081190)		Characterizing human interleukin 9-producing T helper memory cells and their role in Inflammatory and neoplastic skin disease.	30.06.2013	31.12.2024
Durchführung	2541	STD0003476	134/14	Dagmar Simon (I0068240)	ACD	Clinical epidemiology on contact allergen sensitization and allergic contact dermatitis.	31.07.2014	31.03.2028

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	2711	STD0003645	088/13 Amendment	Christoph Schlapbach (I0081190)		Characterizing human interleukin 9-producing T helper memory cells and their role in Inflammatory and neoplastic skin disease.	31.01.2015	31.12.2025
Durchführung	3271	STD0004189	2016-02219	Dagmar Simon (I0068240)		Retrospektive Untersuchung zur Systemtherapie bei Ekzempatienten	31.07.2017	30.12.2024
Durchführung	3327	STD0004243	2016-01686	Dagmar Simon (I0068240)		Epicutaneous tests of cosmetic products to prove skin compatibility.	30.04.2017	30.12.2025
Durchführung	3791	STD0004664	2018-01154	Robert Hunger (I0060960)	MK-3475-716	MK-3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716).	31.12.2018	29.09.2033
Durchführung	3879	STD0004746	2018-01812	Dagmar Simon (I0068240)	M16-045 / Measure Up1	M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis.	31.01.2019	25.11.2024

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	3918	STD0004781	2018-02300	Dagmar Simon (I0068240)	AD Systemtherapie	Retrospective study on systemic therapy of atopic dermatitis.	31.01.2019	31.12.2025
Durchführung	3928	STD0004791	2018-02207	Laurence Feldmeyer (I0310392)		Defining the molecular landscape of cancer-associate stroma in cutaneous squamous cell carcinoma in clinical specimen.	31.01.2019	28.02.2025
Durchführung	4073	STD0004919	2019-00665	Laurence Feldmeyer (I0310392)		Basal cell carcinoma associated to dermatofibroma : induction phenomenon or true tumor?	30.06.2019	28.02.2025
Durchführung	4085	STD0004931	2018-01518	Robert Hunger (I0060960)	CA045001/18-214-08	CA045-001 - A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.	30.11.2019	29.11.2024
Durchführung	4109	STD0004950	2019-01068	Christoph Schlapbach (I0081190)	DisSECT	DisSECT - Disease modelling in Skin Explant Cultures.	31.07.2019	31.12.2024

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	4112	STD0004953	2019-00803	Christoph Schlapbach (I0081190)		PRECISE Identification of biomarkers and therapeutic targets in inflammatory skin disease immunotherapy by high-dimensional single cell analysis, cluster proteomics, and transcriptomics	31.07.2019	31.12.2024
Durchführung	4164	STD0005000	2019-01216	Robert Hunger (I0060960)	NISSO	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the long-term safety and tolerability of Odomzo® (sonidegib) administered in patients with locally advanced basal cell carcinoma (laBCC).	30.09.2019	30.10.2026
Durchführung	4411	STD0005199	2020-00165	Robert Hunger (I0060960)	SUNSHINE EXTENSION	CAIN457M2301 E1, A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa.	30.09.2020	29.09.2025

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	4741	STD0005460	2020-00339	Robert Hunger (10060960)	BERING MELANOMA	Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland – BERING MELANOMA.	31.03.2021	29.09.2027
Durchführung	4803	STD0005608	2021-00940	Dagmar Simon (10068240)		Characteristics of dermatologic, hematologic and allergologic patients with hypereosinophilia	01.07.2021	31.12.2025
Durchführung	4884	STD0005699	2021-00517	Robert Hunger (10060960)		Analysis of the patients with Hidradenitis suppurativa: A retrospective study.	19.08.2021	31.07.2025
Durchführung	4654	STD0005707	2019-02405	Dagmar Simon (10068240)	D3254C00001	A Multicentre, Randomised, Double-blind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Openlabel Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES).	01.05.2021	31.12.2024

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	4946	STD0005813	2020-02713	Dagmar Simon (10068240)	RD.06.SPR.202699	A long-term study to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis	01.11.2021	31.07.2024
Durchführung	4956	STD0005833	2021-01340	Robert Hunger (10060960)		Correlation of histological and peripheral eosinophilic count with survival of malignant melanoma (thicker than 1mm): A prospective study.	02.12.2021	31.10.2026
Durchführung	4954	STD0005839	2021-01723	Robert Hunger (10060960)		A Retrospective Comparison of Patients with Primary and Metastatic Melanoma.	02.12.2021	30.11.2026
Durchführung	5023	STD0005921	2021-02015	Simone Cazzaniga (10309913)	CP-derma1	Multicenter case-control study on risk factors for generalised chronic pruritus, with focus on patients' comorbidities and medications intake.	01.12.2021	31.12.2024
Durchführung	5107	STD0005998	2021-02056	Simone Cazzaniga (10309913)	MMP-derma1	Retrospective analysis of patients with Mucous Membrane Pemphigoid and associated characteristics.	01.01.2005	28.02.2025

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Durchführung	5134	STD0006028	2022-00205	Dagmar Simon (I0068240)	TREATswitzerland	Treatment and medical care of patients with moderate-to-severe atopic dermatitis - Swiss national clinical registry TREAT Switzerland	01.06.2022	01.06.2027
Durchführung	5330	STD0006246	2022-01499	Robert Hunger (I0060960)		A Retrospective Analysis of Patients with Hair Loss	01.10.2022	31.10.2025
Durchführung	5369	STD0006323	2022-01620	Laurence Feldmeyer (I0310392)		Epidemiologische 5-Jahres-Studie über die klinischen, biologischen, histologischen, bildgebenden und therapeutischen Charakteristika von Melanompatienten am Inselspital, Universitätsspital Bern	01.01.2023	31.12.2024
Durchführung	5481	STD0006437	2022-02058	Laurence Feldmeyer (I0310392)		Prospective observational study of dermatological immunerelated adverse events in oncology patients receiving immune checkpoint inhibitors.	31.01.2023	31.01.2025